Open Access. Powered by Scholars. Published by Universities.®
- Discipline
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
A Real World Assessment Of The Efficacy And Safety Of Switching From Tdf To Taf In Treatment Experienced Patients With Hiv Infection, Jaclyn O'Connor, Pharmd Candidate, Kaitlin N. Sassa, Pharmd, Jason J. Schafer, Pharmd, Mph, Bcps Aq-Id, Bcidp, Aahivp
A Real World Assessment Of The Efficacy And Safety Of Switching From Tdf To Taf In Treatment Experienced Patients With Hiv Infection, Jaclyn O'Connor, Pharmd Candidate, Kaitlin N. Sassa, Pharmd, Jason J. Schafer, Pharmd, Mph, Bcps Aq-Id, Bcidp, Aahivp
College of Pharmacy Posters
Objective
- The primary objective of this study was to determine if patients maintain viral suppression after switching from TDF to TAF
- The secondary objective was to assess changes in renal function and serum cholesterol levels
Patients Living With Hiv Infection Are Less Likely To Receive The Correct Statin Intensity For Cardiovascular Disease Risk Reduction, Jason J. Schafer, Pharmd, Mph, Roshni Emmons, Pharmd, Bcps, Nick V. Hastain, Pharmd, Todd Miano, Pharmd, Phd
Patients Living With Hiv Infection Are Less Likely To Receive The Correct Statin Intensity For Cardiovascular Disease Risk Reduction, Jason J. Schafer, Pharmd, Mph, Roshni Emmons, Pharmd, Bcps, Nick V. Hastain, Pharmd, Todd Miano, Pharmd, Phd
College of Pharmacy Posters
- Patients living with HIV (PLWH) are at high risk for atherosclerotic cardiovascular disease (ASCVD)
- Eligible PLWH should receive statins for ASCVD risk reduction according to current guidelines
- Studies suggest that statins are underprescribed in PLWH, but comparisons to uninfected patients and assessments of statin intensity have not occurred
Objective
To determine the influence of HIV infection on appropriate statin prescribing for ASCVD risk reduction